MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma.

Boehringer has made GA one of its R&D priorities, and BI 1584862 is the second candidate in its pipeline to advance into mid-stage clinical testing after BI 771716, an antibody fragment-based ...